SG Trading Solutions LLC Takes $3.08 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

SG Trading Solutions LLC bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, Holdings Channel.com reports. The firm bought 3,992 shares of the biopharmaceutical company’s stock, valued at approximately $3,081,000. Regeneron Pharmaceuticals comprises approximately 0.7% of SG Trading Solutions LLC’s holdings, making the stock its 26th largest position.

A number of other institutional investors have also recently added to or reduced their stakes in the business. MV Capital Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $60,000. Wick Capital Partners LLC acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $507,000. Compound Planning Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 69.3% during the fourth quarter. Compound Planning Inc. now owns 1,676 shares of the biopharmaceutical company’s stock worth $1,294,000 after purchasing an additional 686 shares in the last quarter. Invesco Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 7.2% in the fourth quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company’s stock worth $1,228,127,000 after buying an additional 106,632 shares during the period. Finally, Birchwood Financial Partners Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $32,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on REGN shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $800.00 target price on shares of Regeneron Pharmaceuticals in a report on Thursday, April 23rd. Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Barclays lowered their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. TD Cowen boosted their target price on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a research report on Thursday, April 23rd. Finally, BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $792.65.

Regeneron Pharmaceuticals Trading Up 0.3%

NASDAQ:REGN opened at $609.94 on Friday. The stock has a market cap of $64.48 billion, a price-to-earnings ratio of 14.86, a price-to-earnings-growth ratio of 1.34 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a one year low of $506.38 and a one year high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The business’s 50-day simple moving average is $680.12 and its 200 day simple moving average is $733.15.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same quarter last year, the firm earned $8.22 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 19.0% on a year-over-year basis. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were given a dividend of $0.94 per share. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.16%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the sale, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.